1 0N-SITE TREATMENT OF HEPATITIS C - A PILOT STUDY Shay Keating, MB, PhD Medical Officer.

Slides:



Advertisements
Similar presentations
The Balance of Care Group Alternatives to Hospital MODELS OF INTEGRATED CARE Tom Bowen ORAHS 2008, Toronto, 29 July.
Advertisements

Pharmacology and the Nursing Process in LPN Practice
UNDP RBA Workshop on MDG-Based National Development Strategies Module 4: Health Strategies UN Millennium Project February 27-March 3, 2006.
TRI science addiction Lost Opportunity? SBI for Substance Abuse In ERs and Trauma Centers Academy Health Mady Chalk, Ph.D. Treatment Research Institute.
Targeted Case Management - A Model in Progress Presentation to PAC October 16, 2009.
0 - 0.
Addition Facts
Tackling Dementia Care as a Whole System Paul Forte The Balance of Care Group
Chronic liver disease and substance misuse
Implementing NICE guidance
Implementing NICE guidance
Diabetic Foot Problems
and alcohol dependence
Older People with Dementia in Acute Care: K ey messages from the NAO report Paul Forte The Balance of Care Group
Alcohol misuse - a GP approach 1. 2 Objectives Improve confidence in Detection Assessment Management of problem drinking Improve confidence in Detection.
Richmond House, Liverpool (1) 26 th January 2004.
Main Menu UIC / HBHC Treatment Advocacy Program TAP: Sexual safety 2 12/9/03 1 The University of Illinois at Chicago Howard Brown Health Center Treatment.
© Richard A. Medeiros 2004 x y Function Machine Function Machine next.
Making the Case for Community Based Transitional Care From Prison to the Community Emily Wang, MD Transitions Clinic Southeast Health Center San Francisco.
©2012 MFMER | slide-1 Family History Information Helps Inform Chronic Pain Treatment Elizabeth Pestka, MS, PMHCNS-BC, APNG Cynthia Townsend, PhD, LP Emily.
Slide #1 Case Study Objectives: Darrel At the conclusion of this case study, learners will be better able to: Predict challenges to HIV care and treatment.
2008 Johns Hopkins Bloomberg School of Public Health Setting Up a Smoking Cessation Clinic Sophia Chan PhD, MPH, RN, RSCN Department of Nursing Studies.
1 Preparing for Smallpox: Post-event Smallpox Response.
AAFP Office Champions Leading Tobacco Cessation in FQHCs
2014 National Patient Safety Goals
For the Healthcare Provider
HEPATITIS C Basic Awareness Viral Hepatitis Team Members: Christine Landon (Lead Nurse) Debbie Jones (Specialist Nurse) Alka Maru (Support Nurse) Tracy.
Mady Chalk, PhD., MSW Treatment Research Institute November, 2013.
Addition 1’s to 20.
25 seconds left…...
HCV Infection in Marginalized Populations
Week 1.
Institute for Public Health, Medical Decision Making and Health Technology Assessment 1 Results of the PanEuropean Hepatitis C Project 3 rd Paris Hepatitis.
A Pilot Study of Satisfaction and Adherence with Antipsychotic Medication Amongst Prisoners Dr Alice Mills Mr Dan Bressington Dr Richard Gray Professor.
Wisconsin D.O.C. Approach to Hepatitis C Treatment Edward Wall Secretary Jim Greer Bureau Director Health Services Wisconsin Department of Corrections.
Specific issues and guidelines for HCV treatment in IDUs Bern d Schulte Centre for Interdisciplinary Addiction Research (CIAR), University Hamburg.
TB recurrence & treatment B 陳名揚. Successful treatment more than one drug to which the organisms are susceptible appropriate doses take drugs regularly.
Liver Disease and Thalassaemia George Constantinou.
St John’s Community Hospital Administration of IV Antibiotics Administration of Intravenous Antibiotics in St. John’s Community Hospital Melissa Kelly.
Dr. Elaine Dunnea, Dr. Maura Dugganb, Dr. Julie O’Mahonyc
Hepatitis C Disease & Treatment.
H EALTH INEQUALITIES IN THE NEW EU MEMBER STATES AND CANDIDATE COUNTRIES.
“The ACSS team serves primarily individuals who are experiencing a major mental illness requiring longer term case management in the community to achieve.
Dr Vishelle Kamath Consultant Psychiatrist SEPT
Treating Hepatitis C in Methadone Patients: With Planning, it Works! Patricia Perkins, MS, MPH Independent Healthcare Consultant Community Advisory Board.
NICE Guidelines on the Use of Ribavirin and Interferon Alpha for Hepatitis C Matt Johnson and Dr. Hunt / Asante / Jenkins.
Hepatitis C, Drug Use and Stigma Liz Allen. What it is Hepatitis C? Hepatitis C is a blood-borne virus Can cause serious damage to the liver First indentified.
1 First Clinic Visit for Patients with HIV Infection HAIVN Harvard Medical School AIDS Initiative in Vietnam.
BY: FARWA MOLOO U29/35723/2010 SUPERVISOR: DR AMUGUNE.
Maxime Journiac : ANRS-ISVHLD Paris July Obstacles to Hep C TREATMENT: The patient’s point of view.
SOHO RAPID ACCESS CLINIC. AIMS: n To provide a client focussed, low threshold flexible prescribing service. n To offer an easily accessible assessment.
Module IV: Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals.
HEPATITIS MOBILE TEAM News Tools of screening viral hepatitis in real life: the french model of care André-Jean REMY (1,2), Hugues WENGER (1), Hakim BOUCKHIRA.
1 Kennedy Roberts Senior Medical Officer and Clinical Lead North Cluster Glasgow Addiction Services Community Addiction Teams What are the challenges for.
Section 5: Principles of Drug Addiction Treatment 1.
Social and medical care of intravenous drug users in the Central Bohemian Region Czech Republic PhDr. Pavla Doležalová regional anti-drug coordinator.
Module IV - Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS.
Bringing Hepatitis C Treatment into the Medical Home A Pilot Program for Drug Users Dr. Joanna Eveland MS, MD, Clinical Chief for Special Populations Mission.
Hepatitis C Needs Assessment: Contributions from the National HCV Diagnosis and Local Clinical Databases.
Lighthouse Supporting People Service A Pilot Service for HIV + people A Partnership Between the two Supporting People Administering Authorities of Lambeth.
Trends in Treatment of Recurrent Hepatitis C After Liver Transplantation Kate Forgan-Smith KA Stuart 1,4, C Tallis 1,4 GA Macdonald 1,3,4, J Fawcett 2,3.
Making Every Contact Count (MECC) and Optimising Outcomes Dr Siân Griffiths Consultant in Public Health Medicine.
North Middlesex University Hospital
Dr. Iram Shad PGT-Medicine MU-1, HFH,RWP
Effectiveness of Sofosbuvir in terms of sustained virological response at 12 weeks after treatment (SVR12) BETWEEN treatment naïve AND treatment.
No one gets left behind: Addressing the hidden burden of hepatitis C related advanced liver disease in PWID in the community John S Lambert, MD, PhD.
Peaceful Spirit Treatment Center
Just when you thought you knew everything.
Professor Jack Lambert
Vision Transformative collaboration that fosters resilient self-sustaining Recovery Communities. Mission To develop and sustain measurable solutions that.
Presentation transcript:

1 0N-SITE TREATMENT OF HEPATITIS C - A PILOT STUDY Shay Keating, MB, PhD Medical Officer

2 Background World Health Organisation – 170 million people infected with hepatitis C world-wide 80% of Intravenous Drug Users in the Dublin area (approximately 10,000) are thought to be have been exposed Without treatment, as many as 20% are expected to develop liver cirrhosis in 20years – 6% liver Ca. 6 genotypes world-wide, genotypes 1 and 3 commonest in Intravenous Drug Users in Dublin

3 Who to treat? It has been projected that hepatitis C will represent a substantial economic burden in the US over the next years – this may be reflected here Treatment is believed to be cost effective Ideally everyone who is infected with hepatitis C should be offered treatment. Genotype non-1 more responsive to current treatment

4 Goals of treatment Viral clearance Slow or reverse the disease progression Reduce the risk of hepatocellular carcinoma Improve health related quality of life

5 Current treatment of hepatitis C Very effective, especially with genotype non-1 Pegylated interferon – subcutaneous injection once a week Ribavirin – capsule – twice a day Treatment lasts 24 – 48 weeks according to genotype Success of treatment – sustained viral clearance

6 Side-effects of treatment Interferon Flu-like symptoms Haematological problems Depression – up to 30% of patients Ribavirin Anaemia Fetal abnormalities – contraception is essential

7 Treating Hepatitis C positive drug users Many unstable regarding drug and alcohol use Many drug users do not keep out-patient hospital appointments Adherence to treatment is often poor – chaotic lifestyles, homelessness, unemployment, poverty Retention in treatment can be poor – side effects not well tolerated Relapse into active addiction - a real possibility

8 On site treatment at the DTCB Rationale: To treat the patients with hepatitis C in the same location in which they receive their methadone with a view to retaining the patients in treatment Regular medical review with referral pathway to specialist care Regular psychiatric review – monitor for psychiatric complications/relapse into active addiction

9 On-site hepatitis C treatment pilot study Pilot study of nine patients all hepatitis C positive drug stable Directly observed therapy initiated at DTCB in liaison with Dr. Colm Bergin at St. Jamess hospital Regular psychiatric review by Dr. Jacinta OShea, registrar to Dr. Eamon Keenan

10 Pilot study Not to show that the treatment works But A proof of concept – that patient retention in treatment can be improved if therapy is initiated in a specialist drug treatment setting with directly observed therapy and with appropriate medical and psychiatric support on site.

11 The hepatitis C treatment team Medical Officer Direct liaison with Dr. Colm Bergin - Consultant in Infectious Diseases. St. James Hospital, Dublin. Psychiatric Registrar Under the guidance of Dr. Eamon Keenan – Consultant Psychiatrist in Substance Misuse, DTCB Dedicated Nurse Ms. Anne Bolger, Hepatitis C Liaison Nurse, DTCB Dedicated Counsellor Mr. Alan Furlong. Senior Counsellor, DTCB

12 Study phases Phase 1 Patient Recruitment – commenced March Phase 2 Treatment Phase 3 Follow up

13 To date………… 9 patients have been recruited 8 have continued on treatment Results of the study will be presented in February 2004, at end of the pilot study.

14 Efficacy and Tolerability Preliminary finding suggest that the treatment efficacy is comparable to that of a hospital based hepatitis C treatment setting 5 of the 9 patients experienced haematological difficulties, 4 of whom were supported haematologically on-site 5 out of 9 reported significant depressive symptoms – were treated on-site 3 out of 9 relapsed briefly into active addiction – addressed on the day

15 Cost Financial cost of treatment has many components – medical, nursing, administration, laboratory – comparable to a hospital based clinic The cost of on-site haematological support is offset by the savings on hospital admission

16 Conclusion This pilot study appears to validate the proof of concept that that patient retention in treatment can be improved, for drug users, if therapy is initiated in a specialist drug treatment setting with in- site directly observed therapy and appropriate nursing, medical, psychiatric and counselling support

17 Thank You